Navigation Links
SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
Date:5/11/2010

MENLO PARK, Calif., May 11 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma (MM). The new research was recently presented at the annual meeting of the American Association for Cancer Research (AACR), held in Washington, D.C.

Multiple myeloma is a cancer of the immune system that affects plasma cells in bone marrow. It is the second most common blood-based malignancy (after lymphoma), affecting approximately 20,000 new patients each year.

"More effective treatment options for multiple myeloma are urgently needed and the SRI cancer drug discovery team is actively working on developing next-generation agents that may extend the lives of patients and lead to a cure," said Lidia Sambucetti, Ph.D., senior director of SRI's Center for Cancer Research.

SR16388 has been shown to have excellent oral bioavailability and a favorable safety profile.  In studies, it has shown to potently inhibit angiogenesis in lung and prostate cancers. Based on in vitro and in vivo preclinical data, SRI researchers believe that SR16388 has promise as a new therapeutic for the treatment of multiple myeloma. In the new work presented at AACR, researchers demonstrated that SR16388 inhibits the growth of multiple myeloma cells and experimental tumors. This agent is different from current multiple myeloma therapies in that it works by blocking the ability of cancer cells to survive and grow in hypoxic (low oxygen level) microenvironments that are typical of this malignancy. In part, the drug does this by inhibiting the development of new blood vessels that supply oxygen and nutrients to multiplying cancer cells. SR16388 is currently in late-stage preclinical development, which will prepare the agent for entry into human clinical trials.

About SRI's Biosciences Division

SRI's Biosciences Division carries out basic research, drug discovery, and drug development, and provides contract services. SRI has all of the resources necessary to take R&D from idea to IND®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and other clients and partners advance well over 100 drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2009, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medicomps Decipher Holter Monitor Provides Cardiac Reporting on the International Space Station
2. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
3. Lexicon to Present at BIO International Convention
4. Phytomedics Inc. To Present at BIO 2010 International Convention
5. Systech International(R) Celebrates 25 Years of Innovating Packaging Technology Solutions
6. International Merchant Advisors to Develop Organic Science Branded Medical Marijuana Product Line
7. Winner Medical Participates in CMEF 2010, China International Medical Equipment Fair, in Shenzhen
8. International Merchant Advisors Completes All Stock Based Purchase of Medical Marijuana Company Organic Science, Inc.
9. Essilor Acquires FGX International, Becoming a Major Player in a New Fast-Growing Market
10. PricewaterhouseCoopers to Present First International Market Scorecard on Medical Technology Innovation at the 2010 International Medical Device Industry Compliance Congress
11. Bacterin International Introduces OsteoSelect(R) DBM Putty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... management, presents its enhanced Pepper Flow promotional review platform at the Promotional ... Flow’s increased insight-driven capabilities help marketers streamline the medical, legal, and regulatory ...
Breaking Medicine News(10 mins):